Does Aetna Cover Foundayo? 2026 Coverage by Plan Type

Does Aetna cover Foundayo? Here's the bottom line in one screen.

Does Aetna cover Foundayo right now?

Aetna coverage for Foundayo is plan-specific, and we couldn't verify broad public coverage in the April 2026 documents we checked. Foundayo (orforglipron) does not appear in Aetna's 2026 Standard Plan or 2026 Advanced Control Plan public drug guides. Wegovy oral and Wegovy injection do. Zepbound is listed as non-formulary. Aetna's pharmacy benefit manager, CVS Caremark, removed Zepbound from its template formularies effective July 1, 2025 and stated it was not making GLP-1 coverage changes effective January 1, 2026.

Here's the honest read. Foundayo got FDA-approved on April 1, 2026 — 23 days before this page was last verified. Lilly accepted prescriptions immediately, LillyDirect shipping started April 6, and broader pharmacy and telehealth availability followed shortly after. That timeline puts Foundayo in the window where it's commercially available but hasn't yet completed the formulary review process at most major insurers.

That said, “not on the public formulary we checked” doesn't mean “no Aetna plan covers it.” Aetna isn't one formulary — it's hundreds. Your employer may have negotiated a custom plan that includes Foundayo. You may be eligible for a formulary exception. Aetna Medicare Advantage members will have a separate path through the CMS Medicare GLP-1 Bridge starting July 1, 2026.

The only final answer is the one your specific plan returns when you check it.

Is Foundayo on Aetna's 2026 formulary?

No, Foundayo is not currently listed on Aetna's 2026 Standard Plan or Advanced Control Plan public drug guides as of April 24, 2026. Wegovy (semaglutide) is listed as preferred brand on both. Zepbound (tirzepatide) is listed as non-formulary on both. CVS Caremark — the pharmacy benefit manager that handles Aetna's pharmacy claims — has stated that GLP-1 coverage changes were not part of its January 2026 formulary update and that it continues to evolve its strategy based on market dynamics and the GLP-1 pipeline.

What we actually checked (April 24, 2026)

The Aetna Standard and Advanced Control drug guides state the formulary is updated the first week of each month. We re-check Foundayo's status on this page monthly.

What “no text match” doesn't mean

It doesn't mean every Aetna plan excludes Foundayo. Some employer plans use custom formularies and may add Foundayo separately — Foundayo's $149/month cash floor is unusually low for a brand-name GLP-1, which makes it attractive to employers writing their own GLP-1 benefit policies. It also doesn't mean Aetna will never add Foundayo. Watch for monthly formulary updates if you want to track it yourself.

When Aetna might add Foundayo

We don't have a verified Aetna timeline for adding Foundayo. The signal worth watching: CVS Caremark's January 2026 formulary update did not change GLP-1 coverage. The next windows for changes are subsequent monthly updates. Aetna and CVS Caremark evaluate new drugs based on cost, clinical data, and member demand.

In March 2026, Hims and Hers signed a partnership with Novo Nordisk to broaden Wegovy access, which suggests Wegovy will continue to be the preferred semaglutide on most major formularies. Foundayo competes with Wegovy on price, not preference, which could either accelerate or slow the formulary clock depending on how Aetna's P&T (Pharmacy & Therapeutics) committee weighs cost against existing contracts.

Does CVS Caremark cover Foundayo?

CVS Caremark is the pharmacy benefit manager for most Aetna pharmacy plans, and Foundayo did not appear in the CVS Caremark template formularies we checked for January 2026. A summary of CVS Caremark's 2026 formulary changes from Pharmaceutical Strategies Group (PSG) confirms that CVS removed Zepbound from its formularies effective July 1, 2025 and was not making GLP-1 coverage changes effective January 1, 2026. CVS Caremark's own published page acknowledges it will continue to evolve its GLP-1 strategy as the pipeline develops.

If you have Aetna and your pharmacy benefit is administered by CVS Caremark — most Aetna commercial plans are — your plan formulary is built from a CVS Caremark template plus any custom additions or exclusions your employer made. When you call Aetna and the rep tells you to talk to CVS Caremark for pharmacy questions, that's why.

The CVS Caremark phone number for pharmacy benefits is on the back of your Aetna ID card. Ask for the pharmacy benefit specialist team if the first rep can't answer Foundayo-specific questions.

Related: Does CVS Caremark cover Foundayo?

Why two people with Aetna can get completely different answers

Aetna isn't one health plan — it's a brand sitting on top of hundreds of distinct plan designs. A 2026 commercial plan you bought through the marketplace may cover Foundayo through a formulary exception. A self-funded employer plan administered by Aetna may cover it outright if HR opted in. A standard Aetna PPO from a small employer may exclude all weight-loss medications. Same logo on the card, very different answers.

Three things drive the difference:

1. Plan type. Commercial vs. Medicare Advantage vs. Medicaid (Aetna Better Health) vs. employer self-funded each have entirely different rules.
2. Employer benefit design. Aetna's own GLP-1 benefit page tells employers they can customize whether their plan covers GLP-1s for weight management at all. Many employers exclude weight-loss meds to control costs.
3. Formulary tier and PA criteria. Even if your plan covers Foundayo, you may need prior authorization, step therapy through Wegovy first, or documentation of weight-related comorbidities before approval.

This is also why “Aetna covers Wegovy but not Foundayo” is the most common 2026 answer right now. Wegovy completed Aetna's formulary review years ago. Foundayo is new.

What prior authorization, formulary exception, and benefit exclusion actually mean

These three terms get used interchangeably in casual conversation, but they're very different decisions and they have different fixes. Knowing which one applies to your plan determines what your next step is — and whether fighting for coverage is worth the effort.

How to tell which one you're dealing with

If you've already been denied, the denial letter says it directly. The phrasing matters:

• “Drug requires prior authorization” → fixable with paperwork
• “Drug is not on the formulary” → exception process; possible with the right documentation
• “Weight-loss medications excluded under your plan” → contract-level exclusion; standard appeals usually don't reverse this
• “Step therapy required” → try the preferred drug first, or document why you can't
• “Diagnosis does not meet criteria” → your prescriber needs to add the right ICD-10 codes

If you haven't been denied yet — you're calling Aetna ahead of a prescription — ask the rep specifically: “Is Foundayo covered, non-formulary, or excluded under my plan?” Make them say which of the three it is. Don't accept “it depends.”

For Aetna Standard Plan members, Aetna's documented medical-exception process states it will contact the member or prescriber with a coverage decision within 24 hours of receiving the request. Other PA and appeal timelines vary by plan and request type.

Best for commercial Aetna members. Not for Medicare, Medicaid, or VA.

How to check your specific Aetna plan's Foundayo coverage in 60 seconds

Three ways to verify, ranked by speed. The fastest is Ro's free GLP-1 Insurance Coverage Checker — Ro contacts your insurance plan and emails you a personalized coverage report. The next fastest is logging into Aetna.com and using their Find a Medication tool. The slowest is calling Aetna's member services line — but it's also the most thorough because a real rep can confirm exclusions and PA criteria your member portal might not display clearly.

What to ask Aetna or CVS Caremark about Foundayo (phone script + NDCs)

Use this script verbatim when you call. It cuts through the standard “depends on your plan” answer by forcing the rep to check the specific drug, the specific use case, and the specific decision pathway. Most members give up on Aetna calls because they don't know what to ask. This script gets you a usable answer in one call.

Copy-paste phone script

“Hi, I'm a member calling to check pharmacy benefit coverage for a specific medication. The drug is Foundayo, also known by the active ingredient orforglipron. It's a once-daily oral GLP-1 for chronic weight management, FDA-approved on April 1, 2026.

Three questions:

One — Is Foundayo covered under my current pharmacy benefit, non-formulary but eligible for exception, or excluded entirely under a weight-loss medication exclusion?

Two — If covered or exception-eligible, what are the prior authorization criteria? I want to know the BMI threshold, any required comorbidities, step therapy requirements, and quantity limits.

Three — Can you check both the brand name ‘Foundayo’ and the active ingredient ‘orforglipron’ in the system, and search by NDC if needed, since the drug is new and may be filed under either name?

Also — does my plan have any weight-management or anti-obesity medication exclusion at the contract level?”

Foundayo NDCs to give the rep

CMS published Foundayo NDCs as part of the Medicare GLP-1 Bridge documentation. If the rep can't find Foundayo by name, asking them to search by NDC often surfaces the drug in their system before the brand name index updates. Verify the current NDC list against Lilly's official prescribing information before sharing with the rep, because NDCs can be added per dose and per package size.

Information to have ready before you call

• Your member ID (front of card)
• Your group number (front of card)
• Your prescriber's NPI number (their office can give it to you)
• Your height, weight, BMI
• Any weight-related conditions you've been diagnosed with (high blood pressure, type 2 diabetes, obstructive sleep apnea, high cholesterol, fatty liver disease, PCOS)
• Pen and paper

What to write down during the call

• Date and time of call
• Rep's first name (don't ask for last name; they won't give it)
• Reference number for the call
• The exact answer to each of the three questions
• Any specific PA forms or fax numbers they give you

If you've been denied: appeal options

1. Formulary exception request — if Foundayo is non-formulary (not outright excluded), your prescriber submits a letter of medical necessity. This is the first step for non-formulary drugs.
2. External review — if the internal appeal is denied, request external review by an independent third party. State law often requires plans to offer this for fully-insured commercial plans.
3. State complaint — if you believe the denial violates state mandates, file a complaint with your state insurance commissioner.

When to stop fighting and go cash-pay

Three signs you're dealing with a contract-level exclusion that won't budge through standard appeals:

1. The denial letter explicitly says “weight-loss medications excluded under your plan”
2. Wegovy, Zepbound, Saxenda, and Foundayo are all denied for the same reason
3. Your HR department confirms the plan was sold without obesity treatment coverage

In that case, your two realistic options are:

• Cash-pay Foundayo at $149/month through Ro or LillyDirect Self-Pay
• Talk to your HR team about adding GLP-1 coverage at next year's open enrollment (some employers may add it because of Foundayo's lower price point)

Does Aetna Medicare cover Foundayo?

For Aetna Medicare members, the relevant 2026 path is the CMS Medicare GLP-1 Bridge — a federal program that operates outside the normal Part D coverage flow and includes Foundayo for eligible beneficiaries. The Bridge runs from July 1, 2026 through December 31, 2027. CMS extended the Bridge through 2027 because the BALANCE Model is not launching in Medicare in 2027. The Bridge does not require your Part D plan to opt in. Your prescriber submits the prior authorization through the Bridge process, and the Bridge handles the rest.

What the Medicare GLP-1 Bridge actually does

What to ask your prescriber if you have Aetna Medicare

1. “Are you familiar with the CMS Medicare GLP-1 Bridge starting July 1, 2026?”
2. “Can you submit Foundayo for me through the Bridge process?”
3. “What documentation do you need from me to qualify under CMS criteria?”

Most prescribers writing GLP-1 prescriptions for Medicare patients will become familiar with the Bridge process by mid-2026. If your prescriber hasn't heard of it, point them to the CMS Medicare GLP-1 Bridge page on cms.gov.

What to do before July 1, 2026

If you're an Aetna Medicare member who wants Foundayo right now (April 2026), your options are limited:

1. Wait until July 1, 2026. The Bridge starts then.
2. Use the Foundayo Self-Pay Program until then. Self-Pay is available to Medicare beneficiaries (you agree not to seek reimbursement or apply the cost to Medicare). Pricing: $149–$349/month depending on dose.
3. Ask your prescriber about Wegovy under Medicare's cardiovascular risk reduction indication if you have heart disease risk factors. Wegovy has a separate FDA approval for cardiovascular risk reduction, and Medicare currently covers it in some cases under that specific indication.

What happens after the Bridge ends

CMS extended the Bridge through December 31, 2027 because the BALANCE Model is not launching in Medicare in 2027 as originally planned. Medicaid coverage under BALANCE may launch as early as May 2026, but Medicaid participation depends on individual states and manufacturer participation. We'll update this page as CMS publishes more information about what happens after the Bridge sunsets.

Does Aetna Better Health (Medicaid) cover Foundayo?

Aetna Medicaid coverage for Foundayo is state-specific. The Aetna Better Health “Wegovy CV / Zepbound OSA” Coverage Policy we checked applies to Illinois, Florida, Florida Kids, and Pennsylvania Kids Medicaid plans. That policy excludes Wegovy and Zepbound for weight-loss-only use and does not address Foundayo. CMS says Medicaid coverage under the BALANCE Model depends on state and manufacturer participation and does not guarantee individual coverage.

Why state matters more than the Aetna logo

Aetna Better Health is the Medicaid brand of Aetna, but each state's Medicaid program sets its own rules. Aetna Better Health Florida operates under Florida Medicaid rules; Aetna Better Health Illinois operates under Illinois Medicaid rules. Foundayo coverage depends on your state's preferred drug list (PDL) and the specific Aetna Better Health plan in that state.

How to check your state's Medicaid coverage for Foundayo

1. Search “[your state] Medicaid preferred drug list 2026” or “[your state] Aetna Better Health formulary”
2. Look for “Foundayo” or “orforglipron” in the GLP-1 receptor agonist section
3. If not listed, look for the antiobesity agents section to see if any GLP-1s are covered for weight loss in your state
4. If still unclear, call Aetna Better Health member services for your state

What this means for cash-pay

The Foundayo Commercial Savings Card excludes Medicaid beneficiaries by federal law. The Foundayo Self-Pay Program is a separate program and is available to Medicaid members on a cash-pay basis (you agree not to seek reimbursement from Medicaid or apply the cost to any third-party out-of-pocket requirement). Pricing is $149–$349/month depending on dose.

Related: Does Medicaid cover Foundayo?

Foundayo safety basics every Aetna member should know

Foundayo is FDA-approved for chronic weight management in adults with obesity (BMI ≥30) or adults with overweight (BMI ≥27) plus at least one weight-related medical condition, used together with reduced-calorie diet and increased physical activity. Its FDA prescribing information includes a boxed warning for thyroid C-cell tumors and a contraindication for people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). This is not the full safety profile — please review the full FDA prescribing information at accessdata.fda.gov before starting.

Who should not take Foundayo

Per the boxed warning and contraindications:

• Anyone with a personal or family history of medullary thyroid carcinoma (MTC)
• Anyone with Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Anyone with a known hypersensitivity to orforglipron or any of Foundayo's inactive ingredients

Common side effects in clinical trials

Per Eli Lilly's prescribing information: nausea, constipation, diarrhea, vomiting, indigestion, stomach (abdominal) pain, headache, abdominal swelling, fatigue, belching, heartburn, gas, and hair loss. FDA labeling reports that gastrointestinal adverse reactions occurred more frequently with Foundayo than placebo. Among Foundayo-treated patients reporting GI adverse reactions, 60% were mild, 36% were moderate, and 4% were severe.

More serious risks to discuss with your prescriber

• Pancreatitis (inflammation of the pancreas — stop Foundayo if suspected)
• Gallbladder disease (gallstones, cholecystitis)
• Hypoglycemia (especially if taking insulin or sulfonylurea simultaneously)
• Acute kidney injury (from GI-induced dehydration)
• Increased heart rate
• Suicidal ideation and self-harm (monitor for changes in mood or behavior)

Source: FDA prescribing information for Foundayo (orforglipron), April 2026. Review the full label at accessdata.fda.gov before starting or adjusting treatment.

Frequently asked questions

Related coverage guides

• Does insurance cover Foundayo? (all major insurers)
• Does CVS Caremark cover Foundayo?
• Does Blue Cross cover Foundayo?
• Does Kaiser cover Foundayo?
• How to appeal a Foundayo denial
• Foundayo cost without insurance
• Who qualifies for Foundayo?
• Foundayo vs Mounjaro: the real 2026 comparison